Total Payments
$107,381
2024 Payments
$6,562
Companies
15
Transactions
84
Medicare Patients
890
Medicare Billing
$183,663
Payment Breakdown by Category
Consulting$80,038 (74.5%)
Other$15,670 (14.6%)
Travel$8,611 (8.0%)
Food & Beverage$2,145 (2.0%)
Research$917.08 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $80,038 | 24 | 74.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,670 | 3 | 14.6% |
| Travel and Lodging | $8,611 | 15 | 8.0% |
| Food and Beverage | $2,145 | 40 | 2.0% |
| Unspecified | $917.08 | 2 | 0.9% |
Payments by Type
General
$106,464
82 transactions
Research
$917.08
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $34,997 | 14 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $20,581 | 17 | $0 (2024) |
| GlaxoSmithKline, LLC. | $14,000 | 1 | $0 (2023) |
| Eli Lilly and Company | $9,904 | 23 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $6,921 | 4 | $0 (2024) |
| Exelixis Inc. | $4,903 | 5 | $0 (2019) |
| Genentech, Inc. | $3,554 | 4 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $3,500 | 1 | $0 (2017) |
| Merck Sharp & Dohme LLC | $2,745 | 2 | $0 (2024) |
| Merrimack Pharmaceuticals, Inc. | $2,121 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,562 | 3 | Novartis Pharmaceuticals Corporation ($5,906) |
| 2023 | $19,572 | 6 | GlaxoSmithKline, LLC. ($14,000) |
| 2022 | $4,815 | 5 | Genentech, Inc. ($2,850) |
| 2021 | $3,950 | 2 | Eli Lilly and Company ($2,450) |
| 2020 | $7,193 | 5 | Ipsen Biopharmaceuticals, Inc ($7,193) |
| 2019 | $32,731 | 42 | Ipsen Biopharmaceuticals, Inc ($8,973) |
| 2018 | $25,946 | 14 | Celgene Corporation ($24,707) |
| 2017 | $6,613 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($3,500) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/24/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $45.61 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| 04/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $5,906.25 | General |
| Category: Oncology | ||||||
| 08/07/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 06/04/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $14,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/20/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,610.00 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $144.14 | General |
| 01/13/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $665.08 | Research |
| Study: NCT05417386 | ||||||
| 11/07/2022 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 09/27/2022 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $252.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | ||||||
| 07/28/2022 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $97.81 | General |
| 06/09/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| 01/27/2022 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| 04/27/2021 | Celgene Corporation | Abraxane (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 03/25/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 12/04/2020 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| 10/09/2020 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| 04/20/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 04/05/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 03/20/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 12/05/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $66.44 | General |
| Category: None | ||||||
| 12/04/2019 | Genentech, Inc. | — | Travel and Lodging | In-kind items and services | $596.44 | General |
| 11/15/2019 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $8,625.00 | General |
| 11/15/2019 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $24.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NCT05417386 | Novartis Pharmaceuticals Corporation | $665.08 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $252.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 211 | 444 | $265,622 | $52,579 |
| 2022 | 6 | 239 | 559 | $254,793 | $52,510 |
| 2021 | 7 | 227 | 465 | $197,374 | $45,286 |
| 2020 | 4 | 213 | 382 | $156,459 | $33,288 |
Total Patients
890
Total Services
1,850
Medicare Billing
$183,663
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 108 | 291 | $180,121 | $35,362 | 19.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $28,760 | $5,531 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 46 | 69 | $28,026 | $5,454 | 19.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 40 | $16,640 | $4,030 | 24.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $12,075 | $2,203 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 108 | 331 | $131,767 | $27,010 | 20.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 137 | $55,912 | $11,936 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $30,180 | $6,437 | 21.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 32 | $21,942 | $3,903 | 17.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $11,835 | $2,546 | 21.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 11 | $3,157 | $678.26 | 21.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 253 | $86,312 | $21,551 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 100 | $42,374 | $8,939 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 39 | 43 | $26,851 | $5,514 | 20.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 21 | $17,181 | $3,640 | 21.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $14,832 | $3,362 | 22.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 17 | $5,624 | $1,397 | 24.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 14 | 14 | $4,200 | $883.40 | 21.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 100 | 198 | $96,428 | $18,204 | 18.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 50 | 96 | $31,032 | $6,733 | 21.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 43 | 68 | $12,094 | $4,770 | 39.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $16,905 | $3,582 | 21.2% |
About Dr. Colin Weekes, M.D
Dr. Colin Weekes, M.D is a Medical Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043366750.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Colin Weekes, M.D has received a total of $107,381 in payments from pharmaceutical and medical device companies, with $6,562 received in 2024. These payments were reported across 84 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($80,038).
As a Medicare-enrolled provider, Weekes has provided services to 890 Medicare beneficiaries, totaling 1,850 services with total Medicare billing of $183,663. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Baltimore, MD
- Active Since 01/26/2007
- Last Updated 10/16/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043366750
Products in Payments
- JEMPERLI (Biological) $14,000
- Abraxane (Drug) $9,850
- PLUVICTO (Drug) $5,906
- Cabometyx (Drug) $4,903
- ONIVYDE (Drug) $4,025
- Stivarga (Drug) $3,500
- SOMATULINE DEPOT (Drug) $2,991
- Onivyde (Drug) $2,656
- IMFINZI (Drug) $1,198
- Non-Covered Product (Drug) $66.44
- QINLOCK (Drug) $17.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baltimore
Mario Eisenberger, M.d, M.D
Medical Oncology — Payments: $2.9M
Medical Oncology $2.9M
Dr. Tanguy Seiwert, M.d, M.D
Medical Oncology — Payments: $622,422
Medical Oncology $622,422
Carole Miller, Md, MD
Medical Oncology — Payments: $587,841
Medical Oncology $587,841
Bruce Smith, M.d, M.D
Medical Oncology — Payments: $406,689
Medical Oncology $406,689
Carol Huff, M.d, M.D
Medical Oncology — Payments: $384,580
Medical Oncology $384,580
Leisha Emens
Medical Oncology — Payments: $252,501
Medical Oncology $252,501